Related Experiment Video
Updated: Jul 4, 2026

Extracellular Glucose Depletion as an Indirect Measure of Glucose Uptake in Cells and Tissues Ex Vivo
Published on: April 6, 2022
Peritoneal Glucose Uptake Reduction by Sodium-Glucose Co-Transporter 2 Inhibitors in Clinical Peritoneal Dialysis
Takahiro Kasai1, Yoshito Iida1, Takahide Kimura1
1Division of Nephrology, Department of Internal Medicine, International University of Health and Welfare School of Medicine, Shizuoka, Japan.
Introduction:
In peritoneal dialysis (PD), managing peritoneal glucose uptake is a clinical challenge, as the uptake leads to peritoneal ultrafiltration loss. Peritoneal expression of sodium-glucose co-transporter 2 (SGLT2) suggests that SGLT2 inhibitors, a class of antidiabetic agents, may offer a solution.
Methods:
In 12 PD patients, we examined the influence of dapagliflozin, an SGLT2 inhibitor, on peritoneal equilibration test.
Results:
The volume of drainage and the total glucose content in drainage were larger in the test with dapagliflozin than in that without dapagliflozin (2.41 ± 0.16 vs. 2.23 ± 0.20 L, p = 0.011 and 16.9 ± 3.8 vs. 14.5 ± 3.7 g, p = 0.005, respectively).
Conclusion:
SGLT2 inhibitors could reduce peritoneal glucose uptake and improve fluid removal in clinical PD.
Related Concept Videos
Dipeptidyl Peptidase 4 Inhibitors
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Secondary Active Transport
Secondary Active Transport
Peritoneal Dialysis I: Introduction and Procedure
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are typically...